# Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

> **NCT04704661** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (estimated)

## Conditions studied

- Advanced Breast Carcinoma
- Advanced Colon Carcinoma
- Advanced Colorectal Carcinoma
- Advanced Endometrial Carcinoma
- Advanced Gastric Carcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Salivary Gland Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Clinical Stage III Gastric Cancer AJCC v8
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IV Gastric Cancer AJCC v8
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- HER2-Positive Breast Carcinoma
- Malignant Hepatobiliary Neoplasm
- Metastatic Breast Carcinoma
- Metastatic Colon Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Endometrial Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Salivary Gland Carcinoma
- Stage III Colon Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Stage III Major Salivary Gland Cancer AJCC v8
- Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Stage IV Colon Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Major Salivary Gland Cancer AJCC v8
- Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Unresectable Breast Carcinoma
- Unresectable Colon Carcinoma
- Unresectable Colorectal Carcinoma
- Unresectable Endometrial Carcinoma
- Unresectable Gastric Carcinoma
- Unresectable Gastroesophageal Junction Adenocarcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Salivary Gland Carcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Ceralasertib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT04704661
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-09
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704661, "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT04704661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*